Drug intelligence / Profile preview

HD-NC003

Development stage: Preclinical
Lead developer: Handok
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

HD-NC003 is a preclinical-stage small molecule targeted protein degrader (TPD) being developed through a collaboration between Handok Pharmaceutical, CMG Pharmaceutical, and BNJ Biopharma. The drug candidate is designed to treat solid tumors by selectively inducing the degradation of a specific, undisclosed target protein through the recruitment of the cellular ubiquitin-proteasome system. By utilizing BNJ Biopharma's AI-driven drug discovery platform, the developers aim to identify and optimize degraders that can address oncogenic drivers that are difficult to target with conventional small-molecule inhibitors. The project is currently in the preclinical phase of development.

Beyond the preview

Go deeper on HD-NC003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HD-NC003.

Explore the full profile